These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23933756)

  • 41. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT; Sharma AM
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease.
    Shen Y; Dai Y; Wang XQ; Zhang RY; Lu L; Ding FH; Shen WF
    Cardiovasc Diabetol; 2019 Nov; 18(1):160. PubMed ID: 31733658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
    Ogawa S; Ishiki M; Nako K; Okamura M; Senda M; Mori T; Ito S
    Tohoku J Exp Med; 2011 Feb; 223(2):133-5. PubMed ID: 21304217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antihypertensive and metabolic effects of lacidipine in patients with NIDDM and/or hypertension.
    Galeone F; Giuntoli F; Fiore G; Brunelleschi G; Saba P
    J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S105-7. PubMed ID: 7609495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus].
    Statsenko ME; Derevianchenko MV; Pastukhova OR
    Kardiologiia; 2014; 54(11):20-4. PubMed ID: 25902654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimizing blood pressure control in the obese patient.
    Pischon T; Sharma AM
    Curr Hypertens Rep; 2002 Oct; 4(5):358-62. PubMed ID: 12217253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
    Niswender K
    Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparative analysis of current blood pressure management guidelines in people with and without diabetes.
    Xu Y; Wu S; Niu J; Li M; Lu J; Wang W; He J; Solomon HA; Bi Y; Ning G
    J Diabetes; 2020 Nov; 12(11):781-790. PubMed ID: 32472582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Obesity-Induced Hypertension: New Insights.
    Antza C; Stabouli S; Natsis M; Doundoulakis I; Kotsis V
    Curr Pharm Des; 2017; 23(31):4620-4625. PubMed ID: 28595525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
    Jordan J; Engeli S; Boschmann M; Weidinger G; Luft FC; Sharma AM; Kreuzberg U
    J Hypertens; 2005 Dec; 23(12):2313-8. PubMed ID: 16269974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
    Lan J; Zhao Y; Dong F; Yan Z; Zheng W; Fan J; Sun G
    J Ethnopharmacol; 2015 Feb; 161():69-81. PubMed ID: 25498346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
    Rajeev SP; Cuthbertson DJ; Wilding JP
    Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus.
    Chaturvedi N; Bilous R; Sjolie AK; Klein R;
    Contemp Clin Trials; 2007 Nov; 28(6):780. PubMed ID: 17643353
    [No Abstract]   [Full Text] [Related]  

  • 57. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes.
    Andros V; Egger A; Dua U
    J Manag Care Pharm; 2006 May; 12(4):303-9. PubMed ID: 16792436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Therapy of hypertension in patients with type 2 diabetes mellitus].
    Hess K
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2489-92. PubMed ID: 23114910
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blood pressure lowering effects of rimonabant in obesity-related hypertension.
    Grassi G; Quarti-Trevano F; Seravalle G; Arenare F; Brambilla G; Mancia G
    J Neuroendocrinol; 2008 May; 20 Suppl 1():63-8. PubMed ID: 18426502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.